The General Counsel of Amarin (NASDAQ: AMRN) is Selling SharesBy Carrie Williams
This is Kennedy’s first Sell trade following 9 Buy transactions.
Based on Amarin’s latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $30.17 million and GAAP net loss of $14.53 million. In comparison, last year the company earned revenue of $21.38 million and had a GAAP net loss of $30.53 million. The company has a one year high of $3.65 and a one year low of $1.24. Currently, Amarin has an average volume of 2.22M.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $5.17, reflecting a -40.4% downside.
The insider sentiment on Amarin has been neutral according to 14 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Amarin Corp. Plc is a biopharmaceutical company, which engages in the commercialization and development of therapeutics for cardiovascular health. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.